| Name | Title | Contact Details |
|---|
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.
Global BioChem is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eye Center of Central Georgia is a Macon, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.
BionorImmuno is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.